[go: up one dir, main page]

WO1992005285A1 - Sequences d'oligonucleotides specifiques de sequences de proteines - Google Patents

Sequences d'oligonucleotides specifiques de sequences de proteines Download PDF

Info

Publication number
WO1992005285A1
WO1992005285A1 PCT/US1991/006793 US9106793W WO9205285A1 WO 1992005285 A1 WO1992005285 A1 WO 1992005285A1 US 9106793 W US9106793 W US 9106793W WO 9205285 A1 WO9205285 A1 WO 9205285A1
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotide
sequence
mixture
sequences
complex
Prior art date
Application number
PCT/US1991/006793
Other languages
English (en)
Inventor
Harold Martin Weintraub
Thomas Keith Blackwell
Original Assignee
Fred Hutchinson Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Research Center filed Critical Fred Hutchinson Cancer Research Center
Priority to JP3516179A priority Critical patent/JPH06503715A/ja
Publication of WO1992005285A1 publication Critical patent/WO1992005285A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules

Definitions

  • PROTEIN SEQUENCE-SPECIFIC OLIGONUCLEOTIDE SEQUENCES
  • the invention is directed to a method to identify oligonucleotide sequences which specifically bind target proteins. More specifically, it concerns a method to identify the appropriate oligonucleotide sequence for such binding, and several oligonucleotide sequences which correspond to proteins known to be instrumental in differentiation.
  • RNA oligonucleotides to their complements to inactivate such specific DNA or RNA oligonucleotides which mediate diseases or other undesirable conditions in humans, animals, and even plants.
  • the origin of the term "antisense” is thus clear: the therapeutic or diagnostic oligonucleotide would be the antisense counterpart of the targeted RNA or DNA.
  • the "antisense” oligonucleotides can be supplied directly or generated in situ and may either be conventional oligomers, or are, more commonly, oligomers having properties which make them, for example, resistant to nucleases, more capable of transfer across membranes, or more capable of specific binding to the desired target.
  • the oligonucleo- tides used in this approach may recognize double- stranded DNA by binding to the major or minor grooves present in the double-helix.
  • oligonucleotide-based therapy to include binding to duplexed DNA was made possible by elucidation of the rules governing sequence-specific binding in this context. While not so precisely under- stood as the requirements for base-pair complementation, these principles have been sufficiently described to make de novo design of oligomers which will bind to known target duplexes possible. Such de novo design of specifically binding oligonucleotides is not, however, possible with respect to non-oligonucleotide targets. Formulation of an approach that would permit construc ⁇ tion of oligonucleotides capable of specific binding to any desired target substance would clearly be desirable.
  • oligonucleotides By use of such oligonucleotides, the modulation of the metabolic events associated with any condition, disease, or developmental process for which any critical sub ⁇ stance is known could be effected. Furthermore, the specifically binding oligonucleotides are useful in diagnostic and assay methods and in regulation of cell cultures jln vitro. The method of the invention permits just such design of oligonucleotides comprising seguences specific for any target substance of sufficient size to show complexation with DNA or RNA sequences.
  • the invention method utilizes the polymerase chain reaction (PCR) technique, as described by Saiki, R.K. , et al., Science (1988) 239:487-491.
  • PCR polymerase chain reaction
  • Joyce, G.F. Gene (1989) 82.:83-87 applied the PCR reaction to plus strand RNA/minus strand DNA complexes to study the evolution of RNAs with catalytic activity.
  • Various strategies for producing mutations in RNA to provide the catalytic activity are discussed. Robertson, D.L. , and Joyce, G.F. , in a letter to Nature (1990) 344:467-468. describe the results of application of this technique to obtain a catalytic RNA which cleaves DNA more efficiently than the wild-type enzyme.
  • Randomly synthesized DNA yielding approximately 10 15 i.ndividual sequences was amplified by PCR and transcribed into RNA. It was thought that the complexity of the pool was reduced in the amplification/transcription steps to approximately 10 13 different sequences.
  • the pool was then applied to an affinity column containing the dye and the bound sequences subsequently eluted, treated with reverse transcriptase and amplified by PCR. The results showed that about one in 10 random sequence RNA molecules folds in such a way as to bind specifically to the ligand.
  • Tuerk, C. and Gold, L. in Science (1990) 249:505-510 used what they referred to as the procedure of "systematic evolution of ligands by exponential enrichment" (Selex) which is described as follows: a pool of RNAs that are completely randomized at specific positions is subjected to selection for binding to a desired protein which has been displayed on a nitrocellulose filter. The selected RNAs are then amplified as double-stranded DNA that is competent for subsequent in vitro transcription. The newly transcribed RNA is then enriched for better binding sequences and recycled through this procedure. The amplified selected sequences are subjected to sequence determination using dideoxy sequencing. Tuerk and Gold applied this procedure to determination of RNA ligands which bind to T4 DNA polymerase.
  • Thiesen, H.-J. and Bach, C. Nucleic Acids Res (1990) 18_:3203-3208 described what they call a target detection assay (TDA) to determine DNA binding sites for putative DNA binding proteins.
  • TDA target detection assay
  • a purified functionally active DNA binding protein and a pool of random double-stranded oligonucleotides which contain PCR primer sites at each end were incubated with the protein.
  • the resulting DNA complexes with the protein in their case, the SP1 regulatory protein
  • the invention herein utilizes a binding site selection technique which also depends on the avail ⁇ ability of PCR.
  • selected and ampli ⁇ fied binding sites provide a characteristic imprint of protein binding.
  • this process is aided by consensus sequences.
  • the invention is directed to a method to determine oligonucleotide sequences that specifically bind proteins or other targets.
  • the method is especially applicable to DNAs wherein a consensus sequence site is known. In this case, knowledge of the nature of the protein or other target which is bound is not necessarily a requisite.
  • This technique has been applied to describe the nucleotide sequences responsible for binding certain basic helix-loop-helix (bHLH) proteins which are important in differentiation, specifically MyoD, cMYC and a previously undescribed protein from reticulocytes.
  • bHLH basic helix-loop-helix
  • the invention is directed to a method to determine an oligonucleotide sequence which binds specifically to a target ligand, which method comprises providing a mixture containing oligomers having portions which form a random set of sequences and portions which permit amplification of the oligomers, treating the oligomer mixture with the target substance to form complexes between the target and the oligonucleotides bound specifically thereto, separating the complexes from the unbound members of the oligo- nucleotide mixture, recovering the complexed oligo ⁇ nucleotide(s) and amplifying these. This process will generally be repeated over several rounds of complexation, separation and amplification.
  • the mixture of oligo ⁇ nucleotides having random sequences also contains a consensus sequence known to bind the target.
  • the invention is directed to oligonucleotides identified by the above method, and to oligonucleotide sequences which bind specifically to MyoD, cMYC, and a bHLH protein from reticulocytes.
  • the invention is directed to complexes comprising target substance and specifically bound oligomer in a cell-free environment.
  • the invention is directed to oligomers which contain sequences that bind specifically to target substances, and to the use of these oligomers in therapy, diagnostics, and purification procedures.
  • Figure 1 shows a diagrammatic representation of the method of the invention.
  • Figure 2 shows the DNA sequences of four oligomers used to illustrate the method of the invention.
  • Figure 3 shows typical separation results on an electrophoretic mobility shift assay (EMSA) of free oligonucleotides and bound oligonucleotides to a MyoD- containing fusion protein.
  • ESA electrophoretic mobility shift assay
  • Figure 4 shows typical sequencing results obtained from a control and complexed oligonucleotide recovered from the gel of Figure 3.
  • Figure 5 shows the electrophoretic mobility separation (EMSA) of complexes formed by proteins obtained by in vitro transcription/translation with random and nonrandom oligonucleotide probes.
  • Figure 6 is a higher exposure of the EMSA results of Figure 5, along with a comparable exposure of an EMSA obtained from an additional complexation reaction.
  • ESA electrophoretic mobility separation
  • Figure 7 shows the results of EMSA separations of oligomers retrieved by the process of the invention after additional rounds of complexation, separation, amplification and recovery.
  • Figure 8 shows sequencing results of the control oligonucleotide mixture and various selected oligomers from the mixture obtained from the complexes shown in Figure 7.
  • Figure 9 is a summary of the sequences of oligonucleotides obtained by the selection process of the invention.
  • Figure 10 shows an EMSA separation of proteins from myoblast and MEL cell extracts complexed to oligomer selected using binding to a crude reticulocyte lysate.
  • Figure 11 shows EMSA results of recoveries after selection by method of the invention from randomized oligomers using cMYC fusion proteins.
  • Figure 12 shows the results of sequencing the recovered oligomers of Figure 11 after three rounds of selection.
  • the invention is directed to a method which permits the recovery and deduction of oligomeric sequences that bind specifically to desired targets, including proteins. Therefore, as a result of appli ⁇ cation of this method, oligonucleotides which contain the specifically binding sequences can be prepared and used in oligonucleotide-based therapy and in other applications. For example, these oligonucleotides can be used as a separation tool for retrieving the substances to which they specifically bind. By coupling the oligo ⁇ nucleotides containing the specifically binding sequences to a solid support, for example, proteins or other cellular components to which they bind can be recovered in useful quantities.
  • these oligonucleo ⁇ tides can be used in diagnosis by employing them in specific binding assays for the target substances.
  • the specifically binding oligonucleotides can also be used for in vivo imaging or histological analysis.
  • Oligonucleotides includes RNA or DNA sequences of more than one nucleotide in either single chain or duplex form and specifically includes short sequences such as dimers and trimers, in either single chain or duplex form, which may be intermediates in the production of the specifically binding oligonucleotides.
  • specifically binding oligonucleotides refers to oligonucleotides which are capable of forming complexes with an intended target substance in an environment wherein other substances in the same environment are not complexed to the oligonucleotide. In general, a minimum of approximately 10 nucleotides, preferably 15 nucleotides, are necessary to effect specific binding.
  • the specifically binding oligonucleotides need to contain the sequence- conferring specificity, but may be extended with flanking regions and otherwise derivatized.
  • the specifically binding oligonucleotides may be sequenced, and then resynthesized in any convenient form for the intended use.
  • the oligonucleotides identified by the method of the invention in effect can include modifications both to the backbone structure and to the bases substituted thereon that may confer desirable properties, such as enhanced permeation or increased stability with respect to nucleases.
  • the information obtained by analysis of the oligonucleotide pool obtained as a result of the invention process is thus used in synthesis of oligonucleotides with any desired modification.
  • the oligonucleotides that comprise the sequences specifically binding to target substance may be conventional DNA or RNA moieties, or may be "modified" oligomers which are those conventionally recognized in the art.
  • the oligomers of the invention are defined also to include intermediates in their synthesis, any of the hydroxyl groups ordinarily present may be protected by a standard protecting group, or activated to prepare additional linkages to additional nucleotides, or may be conjugated to solid supports.
  • the 5' or 3' terminal OH is conventionally activated; the alternate terminal 3' or 5 1 OH may be protected.
  • one or more phosphodiester linkages may be replaced by alternative linking groups.
  • alternative linking groups include, but are not limited to, embodiments wherein P(0)0 of the conventional phosphodiester is replaced by P(0)S, P(0)NR_, P(0)R, P(S)S, P(0)OR ! , CO, or CNR 2 , wherein R is H or alkyl (1-6C) and R' is alkyl (1-6C) ; in addition, this group may be attached to adjacent nucleotide through O or S. Not all linkages in the same oligomer need to be identical.
  • oligonu ⁇ cleotides that which incorporate analogous forms of purines and pyrimidines.
  • "Analogous" forms of purines and pyrimidines are those generally known in the art, many of which are used as chemotherapeutic agents.
  • An exemplary but not exhaustive list includes 4-acetylcytosine, 5-(carboxy- hydroxylmethyl) uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethyl- aminomethyluracil, dihydrouracil, inosine, N6-iso- pentenyladenine, 1-methyladenine, l-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiour- acil, beta-D-mannosylqueo
  • the oligonucleotides containing the specific binding sequences discerned through the method of the invention can also be derivatized in various ways. For example, if the oligonucleotide containing the specifically binding sequence is to be used for separ ⁇ ation of the target substance, conventionally the oligo- nucleotide will be derivatized to a solid support to permit chromatographic separation. If the oligonucleo ⁇ tide is to be used to label cellular components or other ⁇ wise for attaching a detectable moiety to target, the oligonucleotide will be derivatized to include a radio- nuclide, a fluorescent molecule, a chromophore or the like.
  • the oligonucleotide is to be used in specific binding assays, coupling to solid support or detectable label, and the like are also desirable. If to be used in therapy, the oligonucleotide may be derivatized to include ligands which permit easier transit of cellular barriers, toxic moieties which aid in the therapeutic effect, or enzymatic activities which perform desired functions at the targeted site. The oligonucleotide may also be included in a suitable expression system to provide for in situ generation of the desired sequence. In general, the oligonucleotides identified according to the method of the invention, and, if desired, synthesized de novo either in native or modified form are useful in a manner analogous to antibodies or specifically immunoreactive fragments thereof.
  • oligonucleotides are characterized by their ability specifically to bind the intended target molecule in both simple and complex environments.
  • the formation of an oligonucleotide-target complex may be formatted in procedures analogous to those employed in immunoassay procedures.
  • a wide range of such protocols is known in the art, and includes both direct and competitive formats, and involves employment of a wide range of detection techniques.
  • antibodies may be used in diagnostic and therapeutic applications, as well as in the control of cell growth and differentiation, so too may the oligonucleotides of the invention.
  • the oligonucleotides used as starting materials in the process of the invention to determine specific binding sequences may be single-stranded or double- stranded DNA or may be RNA. Double-stranded DNA is preferred.
  • the starting material oligo ⁇ nucleotide will contain a randomized sequence portion flanked by primer sequences which permit the application of the polymerase chain reaction to the recovered oligo ⁇ nucleotide from the complex. These flanking sequences may also contain other convenient features such as -13-
  • the randomized portion may be constructed usi g conventional solid phase techniques using mixtures of nucleotides at the positions where randomization is desired.
  • any degree of randomization may ise employed; some positions may be randomized by mixtures o.f only two or three bases rather than the conventional four; randomized positions may alternate with those wfeicfe have been specified. Indeed, it is helpful if some portions of the candidate randomized sequence are in frac known.
  • the target substances are proteins for which consensus sequences are known. While the method of the invention is illustrated using proteins as target substances, any ligand which is of sufficient size to be specifically recognized by an oligonucleotide sequence can be used, as the targe .
  • glycoproteins r proteins carbo- hydrates, membrane structures, receptors, lipids, organelles, and the like can be used as the complexafclr ⁇ i targets.
  • the process is greatly aided if a consensus sequence for the target is known.
  • a particular illustration of this application i, ⁇ set forth in the examples below with respect to the basic-HLH domains which characterize a number of pr ⁇ iteinis involved in development and differentiation of tissu&s.
  • These proteins include a region of basic amino acids which are followed in sequence (N ⁇ C) by a helix-loop— helix region which is thought to mediate multimerizafci ⁇ c of the proteins. The multimerization results in positioning the basic regions so as to make specific contacts with the DNA.
  • DNA sequences wkic ' fc bind proteins containing bHLH regions contain a palindromic consensus region CANNTG. Proteins containing the bHLH region are produced by the gene E2A, MyoD (which is associated with myogenesis and expression of muscle- specific genes) , cMYC (an oncogene) , and other genes involved in development described below.
  • E2A the gene that is associated with myogenesis and expression of muscle- specific genes
  • cMYC an oncogene
  • FIG. 1 An outline of the procedure of the invention is shown in Figure 1. The steps of this process result in "Selected and Amplified Binding-Sites" (SaABs) .
  • SaABs Select and Amplified Binding-Sites
  • a mixture of oligonucleotides is synthesized with random sequences in the intended binding site that are flanked by suitable regions for hybridization to primers for use in PCR.
  • item 1 a single strand DNA is prepared with random nucleotide sequence NNN where the region for primer hybridization,
  • A is shown at the 3' end.
  • the oligomer is formed into a duplex by synthesizing the opposite strand, which now has primer hybridization regions A and B. This is incubated with the target, in this case a protein, and the complexes shown as item 3 are separated from the uncomplexed duplexes using the mobility shift in electro- phoresis (EMSA) .
  • the bound templates are rescued by PCR and amplified for sequencing.
  • the original double- stranded oligonucleotide in item 2 is also amplified as a control.
  • the resulting amplified sequences are applied to sequencing gels to determine the nature of the "ABC" counterparts of the random nucleotides selected.
  • the entire process is repeated using the recovered and amplified duplex until sufficient resolution is obtained.
  • the procedure shown in Figure 1 is merely illustrative.
  • the mixture of oligonucleotides may be comprised of single-stranded DNA or RNA as well as the double-stranded DNA shown.
  • the primer sequences flank the randomized portion on a single oligonucleotide chain.
  • the separation of the portion of the mixture which binds to target substance may be conducted in any convenient manner. For example, rather than relying on a difference in electrophoretic mobility of the complex as compared to the unbound oligonucleotide, the target substance may be coupled with a solid support and the oligonucleotide mixture applied to the support.
  • the procedure simply involves complexation of the mixture with the target, separation of the complexed oligonucleotides from those failing to participate in the complex and rescue of the complexed oligonucleotides by amplification.
  • the amplification of the oligonucleotides which bind to the target may be conducted either while the complex is still intact or after prior separation of the complexed oligonucleotides from the target. In general, more than one "round" of binding, separation of the complex, and amplification will be required in order to achieve a set of appropriately binding oligonucleotides.
  • the process is simply repeated using the recovered subset of binding nucleotides as starting material in subsequent rounds until a mixture containing sufficient binding affinity is obtained.
  • this specifically binding subset it will be desirable to sequence this specifically binding subset to determine consensus sequences in the specifically binding oligomers.
  • the members of this subset may then be synthesized de novo, thus permitting the preparation of oligonucleotides that contain either base modifications, backbone modifications, or both.
  • the oligomers of the invention which contain specifically binding nucleotide seguences are useful in therapeutic, diagnostic and research contexts.
  • the oligomers are utilized in a manner appropriate for oligonucleotide therapy in general—as described above, oligonucleotide therapy as used herein includes any use of oligonu ⁇ cleotides as medicaments, whether this involves targeting a specific DNA or RNA or targeting any other substance through complementarity or through any other specific binding means, for example, sequence-specific orientation in the major groove of the DNA double-helix, or any other specific binding mode.
  • the oligomers of the invention can be formulated for a variety of modes of administration, including systemic and topical or localized administration.
  • the oligomers of the invention are formulated in liquid solu ⁇ tions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addi ⁇ tion, the oligomers may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included.
  • Systemic administration can also be by transmucosal or transdermal means, or the compounds can be administered orally.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration bile salts and fusidic acid derivatives.
  • detergents may be used to facilitate permeation.
  • Transmucosal administration may be through nasal sprays, for example, or using suppositories.
  • the oligomers are formulated into conventional oral administration forms such as capsules, tablets, and tonics.
  • the oligomers of the invention are formulated into ointments, salves, gels, or creams, as is generally known in the art.
  • the oligonucleotides may also be- employed in expression systems, which are administered according to techniques applicable, for instance, in applying gene therapy.
  • the oligomers of the invention may be used as diagnostic reagents to detect the presence or absence of the target substances to which they specifically bind. Such diagnostic tests are conducted by contacting a sample with the specifically binding oligonucleotide to obtain a complex which is then detected by conventional means.
  • the oligomers may be labeled using radioactive, fluorescent, or chromogenic labels and the presence of label bound to solid support to which the target substance has been bound through a specific or nonspecific binding means detected.
  • the specifically binding oligomers may be used to effect initial complexation to the support. Means for conducting assays using such oligomers as specific binding partners are generally known to track those for standard specific binding partner based assays.
  • oligomers of the invention are characterized by their ability to target specific substances regardless of the mechanisms of targeting or the mechanism of the effect thereof.
  • the specifically binding oligonucleotides of the invention are especially helpful in effecting the isolation and purification of substances to which they bind.
  • the oligonucleotide containing the specific binding sequences is conjugated to a solid support and used as an affinity ligand in chromatographic separation of the target substance.
  • the affinity ligand can also be used to recover previously unknown substances from sources which do not contain the target substance by virtue of binding similarity between the intended target and the unknown proteins.
  • insight may be gained as to the mechanisms for control of gene expression.
  • oligonucleotide sequences in the randomized mixtures were synthesized using standard solid-phase synthesis techniques and are shown in Figure 2.
  • the MCK muscle creatine kinase enhancer
  • Oligomers DI, D2 and D3 have various locations of randomization of sequence, and further contain regions for coupling to PCR primers shown as B and A" at the 5' and 3' ends, respectively.
  • Primer A is 5 • -TCCGAATTCCTACAG-3 * and primer B is
  • the double-stranded D1-D3 templates were generated by annealing the oligonucleotide to. a 10-fold molar excess of primer A, synthesizing the complementary strand using Klenow fragment of E. coli DNA polymerase and purifying the template on a 12% polyacrylamide gel.
  • the templates were end-labeled using the kinase reaction of Davis, R.L., et al., Cell (1990) 60:733.
  • the MCK double- stranded template was obtained from a kinased oligo ⁇ nucleotide annealed to its complement.
  • the randomization obliterates a portion of the consensus sequence in each case.
  • randomization is limited to two nucleotides upstream, two nucleotides downstream, and the two nucleotides between the members of the consensus motif.
  • a slice approximately 0.3 cm wide was excised from the dried- down gel including the 3 MM (Whatman) paper backing.
  • the gel slices were incubated at 37 ⁇ C overnight in 0.5 ml of 0.5 M ammonium acetate, 10 mM MgCl, 1 mM EDTA, and 0.1% SDS. Approximately 50% of the radioactivity was recovered.
  • the eluate was extracted twice each with phenol and with chloroform:isoamyl alcohol, 24:1, and precipitated with ethanol. The precipitates were brought to 0.3 M sodium acetate and reprecipitated with ethanol.
  • the recovered and amplified complexed oligomers were then sequenced using labeled primer A or B and the termination step of the Sequenase procedure marketed by United States Biochemical Co. as follows.
  • the primers were labeled using a kinase reaction to 1-2x10 cpm/ng and unincorporated label was removed using a Sephadex G50 spin column. 10 ng labeled primer were mixed with about 5 ng purified oligomer to be sequenced in a 12 ⁇ l reaction that contained 1 ⁇ l Sequenase Mn +2 buffer and 2 ⁇ l 5 x Sequenase buffer. The reaction was incubated at 95°C for 5 min and then quick spun at room temperature for 1 min.
  • the reaction was placed on ice and to it were added 1 ⁇ l 0.1 M dithiothreitol and 2 ⁇ l of diluted Sequenase 2.0 enzyme (1:8 in ice-cold TE, pH 7.4). 3.5 ⁇ l of this mixture were added to 2.5 ⁇ l of each of the Sequenase dGTP termination mixes and incubated at 45°C for 4 min. The reactions were terminated by adding 4 ⁇ l
  • Example 2 DNA Sequences Targeting Various Proteins
  • the D3 oligomer which contains this sequence was used in subsequent studies. While D3 contains the consensus sequence, it is randomized in the immediate proximity.
  • Various proteins which are associated with differentiation including MyoD, E2A, E12, and E47, were synthesized by in vitro translation from DNAs, some of which are reported by Murre, C, et al., Cell (1989) jjj5:777. The transcribed sequences were prepared from a mouse MyoD cDNA, a human E12 cDNA (E12R) and a human E47 cDNA as described by Benezra, R.
  • the final binding reaction to test randomized oligomers contained 20 mm Hepes, pH 7.6, 50 mM KC1, 1 mM dithiothreitol, 1 mM EDTA, 8% glycerol, 0.1 ⁇ g polydl/dC and 2 ⁇ g of a 50 bp single-stranded oligonucleotide, both added as nonspecific competitors.
  • Each binding reaction contained the in vitro synthesized protein species at about 6.9 x 10 M and either 0.15 ng of MCK or 0.30 ng of D2 or D3 labeled templates providing a protein:DNA molar ratio of about 0.18. Binding reactions were performed at room temperature for 20 min and immediately subjected to EMSA. The results of application of these incubation mixtures to EMSA are shown in Figure 5. These results indicate that MCK binds strongly .to E12/MyoD, E47 and E47/MyoD; D3 binds only to E47.
  • Figure 8 shows the results of sequencing performed as described above with some of the complexes shown in Figure 7 which were excised from the gel.
  • Figure 8A gives the results for the D3 control mixture showing complete heterogeneity at the six positions which were randomized.
  • DNA sequences which had been selected by the invention process ( Figures 8B-8F) showed positional preferences.
  • the D3 oligomer selected by complexation to MyoD ( Figure 8B) showed a clear preference for T in positions 5 and 4, retained some heterogeneity in positions 1 and -1, and showed some preference for A in positions -4 and -5.
  • the reticulocyte lysate shown in Figure 8F apparently recognizes the sequence (G/A)CCAGTTG(N)A.
  • Figure 9 A summary of the results of the binding and sequencing experiments illustrated in Figure 8 is shown in Figure 9.
  • the preset position choices are shown on shaded backing, the assignment preferences that are absolute or nearly so are indicated with capital letters, and incomplete preferences are printed in lower case. However, a bar over the letter indicates exactly the opposite—the base is never found at the indicated position (capitals) or only weakly represented (lower case) .
  • MCK and the lysate-derived D3 template were used in complexation reactions, conducted as described above under the following conditions: P2 myoblast binding reactions contain 20 mM Hepes, pH 7.6, 1.5 mM MgCl 2 , 50 mM NaCl, 5% glycerol and 500 ng poly(dI/dC) .
  • MEL cell binding reactions were conducted as described in Example 1, except that each reaction contained 2 ⁇ g of polydl/dC. Both binding reactions were incubated at room temperature for 20 minutes and then immediately subjected to EMSA on 5% polyacrylamide gels at 200 V at 4°C. The results are shown in Figure 10.
  • the lysate- selected D3 binds to factors in the MEL extract; and to different factors from that bound by MCK in the myoblast cell extract. These previously unidentified target proteins are therefore recoverable by virtue of their ability to bind lysate-selected D3.
  • Amplified D3 was used as a control. As indicated in the figure, the two bases internal to the consensus sequence have been identified, but heterogeneity in the flanking sequences persists.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Méthode servant à identifier des séquences d'oligomères qui se lient spécifiquement à des protéines cibles ou à d'autres fractions cibles. La technique comprend la complexation de la substance cible avec un mélange d'oligonucléotides contenant des séquences aléatoires et des séquences qui servent d'amorces pour des réactions en chaîne de polymérases dans des conditions dans lesquelles un complexe se forme avec certains éléments, mais pas tous, du mélange d'oligonucléotides. Le mélange est ensuite séparé des oligonucléotides non complexés et les éléments complexés du mélange d'oligonucléotides sont récupérés du complexe séparé et amplifiés en utilisant la réaction en chaîne de polymérase. On peut procéder à plusieurs tours de sélection en utilisant la complexation, la séparation, l'amplification et la récupération. Le mélange ou les oligonucléotides récupérés peuvent être mis en séquences et cette information peut être utilisée pour la synthèse de novo du(des) oligonucléotide(s) identifié(s). Ces oligonucléotides synthétisés peuvent contenir une ou plusieurs bases ou liaisons de squelette modifiées.
PCT/US1991/006793 1990-09-21 1991-09-18 Sequences d'oligonucleotides specifiques de sequences de proteines WO1992005285A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3516179A JPH06503715A (ja) 1990-09-21 1991-09-18 タンパク質配列特異的オリゴヌクレオチド配列

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58676990A 1990-09-21 1990-09-21
US586,769 1990-09-21

Publications (1)

Publication Number Publication Date
WO1992005285A1 true WO1992005285A1 (fr) 1992-04-02

Family

ID=24347046

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006793 WO1992005285A1 (fr) 1990-09-21 1991-09-18 Sequences d'oligonucleotides specifiques de sequences de proteines

Country Status (4)

Country Link
EP (1) EP0549692A4 (fr)
JP (1) JPH06503715A (fr)
AU (1) AU8547691A (fr)
WO (1) WO1992005285A1 (fr)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533838A4 (en) * 1990-06-11 1993-05-26 Univ Colorado Foundation Nucleic acid ligands
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5672472A (en) * 1991-08-23 1997-09-30 Isis Pharmaceuticals, Inc. Synthetic unrandomization of oligomer fragments
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5707796A (en) * 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5723594A (en) * 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5747253A (en) * 1991-08-23 1998-05-05 Isis Pharmaceuticals, Inc. Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding
US5840867A (en) * 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
EP0736103A4 (fr) * 1993-12-17 1999-07-28 Roger S Cubicciotti Assemblage dirige par nucleotides de medicaments et systemes bimoleculaires et multimoleculaires
WO2001071044A1 (fr) 2000-03-22 2001-09-27 Quantum Dot Corporation Procedes d'utilisation de nanocristaux semi-conducteurs dans des tests d'acides nucleiques a base de billes
WO2003016469A2 (fr) 2001-08-17 2003-02-27 Neose Technologies, Inc. Synthese chimio-enzymatique d'oligosaccharides sialyles
WO2003075765A1 (fr) 2002-03-05 2003-09-18 Board Of Regents, The University Of Texas System Produits de contraste biospecifiques
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
EP0832291A4 (fr) * 1995-06-07 2004-08-04 Gilead Sciences Inc Dosages d'oligonucleotides lies a des enzymes (elona)
WO2005033657A2 (fr) 2003-09-30 2005-04-14 Cytyc Corporation Classement automatise d'echantillons cytologiques
WO2005081721A2 (fr) 2003-12-12 2005-09-09 Quantum Dot Corporation Procede permettant d'ameliorer le transport de nanocristaux semiconducteurs a travers des membranes biologiques
WO2007038658A2 (fr) 2005-09-26 2007-04-05 Medarex, Inc. Conjugues anticorps-medicament et leurs methodes d'utilisation
EP1489171A4 (fr) * 2002-03-19 2008-05-07 Fujitsu Ltd Molecule fonctionnelle et son procede de production
US7507420B2 (en) 2001-05-31 2009-03-24 Medarex, Inc. Peptidyl prodrugs and linkers and stabilizers useful therefor
US7517903B2 (en) 2004-05-19 2009-04-14 Medarex, Inc. Cytotoxic compounds and conjugates
US7538211B2 (en) 2004-02-12 2009-05-26 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
EP2085781A1 (fr) 2000-10-06 2009-08-05 Life Technologies Corporation Cellules dotées d'une signature spectrale et leurs procédés de préparation et leur utilisation
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
US7589073B2 (en) 2004-09-07 2009-09-15 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
US7659091B2 (en) 2004-09-21 2010-02-09 Nourheart, Inc. Diagnostic marker
US7662571B2 (en) 2005-07-14 2010-02-16 Nourheart Inc. Mitochondrial markers of ischemia
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
EP2251380A2 (fr) 2009-05-15 2010-11-17 Millipore Corporation Conjugués de colorants et procédés d'utilisation
US7960102B2 (en) 2002-07-25 2011-06-14 Archemix Corp. Regulated aptamer therapeutics
US7964572B2 (en) 1996-02-01 2011-06-21 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US8017755B2 (en) 2003-05-23 2011-09-13 President And Fellows Of Harvard College RNA-based transcriptional regulators
US8030465B2 (en) 2001-06-29 2011-10-04 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
US8288350B2 (en) 2006-07-05 2012-10-16 Nour Heart, Inc. Methods to prevent and treat diseases
WO2013142255A2 (fr) 2012-03-22 2013-09-26 University Of Miami Agents de liaison multi-spécifiques
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US9279009B2 (en) 2007-12-03 2016-03-08 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services FILIP1L nucleic acid fragments
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
DE102014114834A1 (de) 2014-10-13 2016-04-14 Centrum Für Angewandte Nanotechnologie (Can) Gmbh Nanopartikel enthaltende Polymermizellen in nicht-wässriger Lösung, Methoden zu ihrer Herstellung und ihrer Anwendung
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US10329617B2 (en) 2008-05-08 2019-06-25 The Johns Hopkins University Compositions and methods for modulating an immune response

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772691A (en) * 1985-06-05 1988-09-20 The Medical College Of Wisconsin, Inc. Chemically cleavable nucleotides
EP0252146B1 (fr) * 1986-01-09 1994-05-25 Massachusetts Institute Of Technology Facteurs nucleaires associes a la regulation de la transcription
DE69128350T2 (de) * 1990-06-11 1998-03-26 Nexstar Pharmaceuticals Inc Nukleinsäureliganden

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BioTechniques, Volume 6, Number 10, issued 1988, VANDER KROL et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences," pages 958-976, see page 958, first paragraph. *
Nucleic Acids Research, Volume 17 Number 10, issued 1989, KENNETH W. KINZLER et al., "Whole Genome PCR: Application to the Identification of Sequences Bound by Gene Regulatory Proteins," pages 3645-3653, see Abstract, Figure 1, and page 3645, last paragraph-page 3650, line 6. *
See also references of EP0549692A4 *

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110900A (en) * 1990-06-11 2000-08-29 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands
US5843653A (en) * 1990-06-11 1998-12-01 Nexstar Pharmaceuticals, Inc. Method for detecting a target molecule in a sample using a nucleic acid ligand
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5670637A (en) * 1990-06-11 1997-09-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands
EP0533838A4 (en) * 1990-06-11 1993-05-26 Univ Colorado Foundation Nucleic acid ligands
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5707796A (en) * 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
EP1695978A1 (fr) * 1990-06-11 2006-08-30 Gilead Sciences, Inc. Ligands constitués par des acides nucléiques
US6933116B2 (en) 1990-06-11 2005-08-23 Gilead Sciences, Inc. Nucleic acid ligand binding site identification
EP0786469A3 (fr) * 1990-06-11 1997-08-06 NeXstar Pharmaceuticals, Inc. Ligands d'acide nucléique
EP1493825A3 (fr) * 1990-06-11 2005-02-09 Gilead Sciences, Inc. Procédé pour la production de ligands constitués par des acides nucléiques
US6331398B1 (en) 1990-06-11 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands
US5840867A (en) * 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5747253A (en) * 1991-08-23 1998-05-05 Isis Pharmaceuticals, Inc. Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding
US5672472A (en) * 1991-08-23 1997-09-30 Isis Pharmaceuticals, Inc. Synthetic unrandomization of oligomer fragments
EP0736103A4 (fr) * 1993-12-17 1999-07-28 Roger S Cubicciotti Assemblage dirige par nucleotides de medicaments et systemes bimoleculaires et multimoleculaires
US5723594A (en) * 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
EP0832291A4 (fr) * 1995-06-07 2004-08-04 Gilead Sciences Inc Dosages d'oligonucleotides lies a des enzymes (elona)
US7141375B2 (en) 1995-06-07 2006-11-28 Gilead Sciences, Inc. Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor
US7964572B2 (en) 1996-02-01 2011-06-21 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
EP2365096A1 (fr) 2000-03-22 2011-09-14 Life Technologies Corporation Procédés d'utilisation de nano-cristaux semi-conducteurs dans des analyses d'acide nucléique de billes
WO2001071044A1 (fr) 2000-03-22 2001-09-27 Quantum Dot Corporation Procedes d'utilisation de nanocristaux semi-conducteurs dans des tests d'acides nucleiques a base de billes
EP2085781A1 (fr) 2000-10-06 2009-08-05 Life Technologies Corporation Cellules dotées d'une signature spectrale et leurs procédés de préparation et leur utilisation
US7507420B2 (en) 2001-05-31 2009-03-24 Medarex, Inc. Peptidyl prodrugs and linkers and stabilizers useful therefor
EP2266986A1 (fr) 2001-05-31 2010-12-29 Medarex, Inc. Cytotoxines, promedicaments, lieurs et stabilisateurs utiles pour ceux-ci
US8030465B2 (en) 2001-06-29 2011-10-04 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
WO2003016469A2 (fr) 2001-08-17 2003-02-27 Neose Technologies, Inc. Synthese chimio-enzymatique d'oligosaccharides sialyles
WO2003075765A1 (fr) 2002-03-05 2003-09-18 Board Of Regents, The University Of Texas System Produits de contraste biospecifiques
US7517646B2 (en) 2002-03-19 2009-04-14 Fujitsu Limited Functional molecule and process for producing the same
EP1489171A4 (fr) * 2002-03-19 2008-05-07 Fujitsu Ltd Molecule fonctionnelle et son procede de production
US7960102B2 (en) 2002-07-25 2011-06-14 Archemix Corp. Regulated aptamer therapeutics
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US8017755B2 (en) 2003-05-23 2011-09-13 President And Fellows Of Harvard College RNA-based transcriptional regulators
WO2005033657A2 (fr) 2003-09-30 2005-04-14 Cytyc Corporation Classement automatise d'echantillons cytologiques
WO2005081721A2 (fr) 2003-12-12 2005-09-09 Quantum Dot Corporation Procede permettant d'ameliorer le transport de nanocristaux semiconducteurs a travers des membranes biologiques
US7579456B2 (en) 2004-02-12 2009-08-25 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US7538211B2 (en) 2004-02-12 2009-05-26 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
US7517903B2 (en) 2004-05-19 2009-04-14 Medarex, Inc. Cytotoxic compounds and conjugates
US7589073B2 (en) 2004-09-07 2009-09-15 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
US7659091B2 (en) 2004-09-21 2010-02-09 Nourheart, Inc. Diagnostic marker
US9617546B2 (en) 2005-02-14 2017-04-11 Archemix Llc Aptamer therapeutics useful in the treatment of complement-related disorders
US8236773B2 (en) 2005-02-14 2012-08-07 Archemix Llc Aptamer therapeutics useful in the treatment of complement-related disorders
US11913000B2 (en) 2005-02-14 2024-02-27 Iveric Bio, Inc. Aptamer therapeutics useful in the treatment of complement-related disorders
US10947544B2 (en) 2005-02-14 2021-03-16 Archemix Llc Aptamer therapeutics useful in the treatment of complement-related disorders
US8946184B2 (en) 2005-02-14 2015-02-03 Archemix Llc Aptamer therapeutics useful in the treatment of complement-related disorders
US7662571B2 (en) 2005-07-14 2010-02-16 Nourheart Inc. Mitochondrial markers of ischemia
WO2007038658A2 (fr) 2005-09-26 2007-04-05 Medarex, Inc. Conjugues anticorps-medicament et leurs methodes d'utilisation
EP2354163A2 (fr) 2005-09-26 2011-08-10 Medarex, Inc. Conjugué d'un anticorps anti-cd4 ou anti-psma et duocarmycine
US8288350B2 (en) 2006-07-05 2012-10-16 Nour Heart, Inc. Methods to prevent and treat diseases
US9279009B2 (en) 2007-12-03 2016-03-08 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services FILIP1L nucleic acid fragments
US10329617B2 (en) 2008-05-08 2019-06-25 The Johns Hopkins University Compositions and methods for modulating an immune response
EP2251380A2 (fr) 2009-05-15 2010-11-17 Millipore Corporation Conjugués de colorants et procédés d'utilisation
WO2013142255A2 (fr) 2012-03-22 2013-09-26 University Of Miami Agents de liaison multi-spécifiques
DE102014114834A1 (de) 2014-10-13 2016-04-14 Centrum Für Angewandte Nanotechnologie (Can) Gmbh Nanopartikel enthaltende Polymermizellen in nicht-wässriger Lösung, Methoden zu ihrer Herstellung und ihrer Anwendung
WO2016059019A2 (fr) 2014-10-13 2016-04-21 Centrum Für Angewandte Nanotechnologie (Can) Gmbh Micelles polymères contenant des nanoparticules en solution non aqueuse, leurs procédé de préparation et d'utilisation
WO2016059020A2 (fr) 2014-10-13 2016-04-21 Centrum Für Angewandte Nanotechnologie (Can) Gmbh Micelles polymères contenant des nanoparticules dans une solution non aqueuse, leurs procédés de préparation et utilisation

Also Published As

Publication number Publication date
AU8547691A (en) 1992-04-15
EP0549692A4 (en) 1993-08-25
EP0549692A1 (fr) 1993-07-07
JPH06503715A (ja) 1994-04-28

Similar Documents

Publication Publication Date Title
WO1992005285A1 (fr) Sequences d'oligonucleotides specifiques de sequences de proteines
US5874260A (en) Oligonucleotide which can be used as primer in a method of amplification based on a replication accompanied by strand displacement
Chen et al. RNA editing of apolipoprotein B mRNA. Sequence specificity determined by in vitro coupled transcription editing.
AU596068B2 (en) Defined sequence single strand oligonucleotides incorporating reporter groups, process for the chemical synthesis thereof, and nucleosides useful in such synthesis
Luse et al. Abortive initiation by RNA polymerase II in vitro at the adenovirus 2 major late promoter.
JP3529135B2 (ja) 特定のｒｎａ鎖の切断方法
Green et al. Structural requirements for processing of synthetic tRNAHis precursors by the catalytic RNA component of RNase P.
Wilson et al. Nucleotide sequence of the coding portion of human alpha globin messenger RNA.
Calvet et al. Heterogeneous nuclear RNA double-stranded regions probed in living HeLa cells by crosslinking with the psoralen derivative aminomethyltrioxsalen.
Coin et al. TATA binding protein discriminates between different lesions on DNA, resulting in a transcription decrease
US7303867B2 (en) Method for detecting target nucleotide sequences
DE69323267T2 (de) Sonden für Mycobacterium Avium, Mycobacterium Intracellulare, und Mycobacterium Paratuberculosis
EP1337547B1 (fr) Methode a base de nuclease permettant de detecter et de quantifier des oligonucleotides
De Boer et al. In vivo transcription of rRNA operons in Escherichia coli initiates with purine nucleoside triphosphates at the first promoter and with CTP at the second promoter.
Chesselet In situ hybridization histochemistry
Sekiya et al. Total synthesis of a tyrosine suppressor transfer RNA gene. XVI. Enzymatic joinings to form the total 207-base pair-long DNA.
Schaefer et al. Ribosome-binding sites and RNA-processing sites in the transcript of the Escherichia coli unc operon
Thrall et al. DNA polymerase, RNA polymerase and exonuclease activities on a DNA sequence modified by benzo [α] pyrene diolepoxide
WO1990008838A1 (fr) Marquage d'acides nucleiques a l'aide de marqueurs fluorescents
AU767490B2 (en) Method for quantitating oligonucleotides
JP2001525180A (ja) タンパク質及び遺伝子を迅速同定するための選択的方法並びにその使用
EP1299562A1 (fr) Expression genique dans des etats biologiques
JP7711944B2 (ja) オリゴ核酸分子及びその急性間欠性ポルフィリン症の治療における応用
Militello et al. Transcriptional and post-transcriptional in organello labelling of Trypanosoma brucei mitochondrial RNA
JP3513068B2 (ja) 生細胞の細胞質内標的核酸を検出する方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP KR NO SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

ENP Entry into the national phase

Ref document number: 2090330

Country of ref document: CA

Ref country code: CA

Ref document number: 2090330

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1991917153

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991917153

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1991917153

Country of ref document: EP